Global Pneumococcal Vaccine Market Size & Outlook
Global pneumococcal vaccine market, 2018-2030 (US$M)
Related Markets
Global pneumococcal vaccine market highlights
- The global pneumococcal vaccine market generated a revenue of USD 8,070.9 million in 2023 and is expected to reach USD 12,191.7 million by 2030.
- The market is expected to grow at a CAGR (2024 - 2030) of 6.1% by 2030.
- In terms of segment, pneumococcal conjugate vaccine accounted for a revenue of USD 7,514.2 million in 2023.
- Pneumococcal Conjugate Vaccine is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2023.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
Global data book summary
| Market revenue in 2023 | USD 8,070.9 million |
| Market revenue in 2030 | USD 12,191.7 million |
| Growth rate | 6.1% (CAGR from 2023 to 2030) |
| Largest segment | Pneumococcal conjugate vaccine |
| Fastest growing segment | Pneumococcal Conjugate Vaccine |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine |
Other key industry trends
- In terms of revenue, the North America accounted for 75.4% of the global pneumococcal vaccine market in 2023.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, Canada is the fastest growing regional market and is projected to reach USD 645.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pneumococcal Vaccine Market Scope
Pneumococcal Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global pneumococcal vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pneumococcal vaccine market will help companies and investors design strategic landscapes.
Pneumococcal conjugate vaccine was the largest segment with a revenue share of 93.1% in 2023. Horizon Databook has segmented the Global pneumococcal vaccine market based on pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Pneumococcal Vaccine Vaccine Type Outlook (Revenue, USD Million, 2018-2030)
- Pneumococcal Conjugate Vaccine
- Pneumococcal Polysaccharide Vaccine
- Global Pneumococcal Vaccine Product Outlook (Revenue, USD Million, 2018-2030)
- Prevnar 13
- Synflorix
- Pneumovax 23
- VAXNEUVANCE
- PNEUMOSIL
- Other Products
- Global Pneumococcal Vaccine End Use Outlook (Revenue, USD Million, 2018-2030)
- Public Sector
- Private Sector
Reasons to subscribe to Global pneumococcal vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global pneumococcal vaccine market databook
-
Our clientele includes a mix of pneumococcal vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global pneumococcal vaccine market, including forecasts for subscribers. This global databook contains high-level insights into Global pneumococcal vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global pneumococcal vaccine market size, by regions, 2018-2030 (US$M)
Top 10 countries: Pneumococcal vaccine market size, 2023 (US$M)
Global pneumococcal vaccine market share, by vaccine type, 2023 & 2030 (%, US$M)
Pneumococcal vaccine market: Opportunity assessment by country
Global pneumococcal vaccine market, by region, 2023 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
